Eclipseregenesis
1 known investors
Eclipse Regenesis develops the Eclipse XL1, a device-based regenerative therapy that stimulates new intestinal tissue growth to treat patients with Short Bowel Syndrome (SBS). The company operates in the medical device and gastrointestinal care space as an alternative to parenteral nutrition, drug therapy, and transplantation.
BiotechHealthtechMedical Devices
Investors · 1
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2023 | $970.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $423.2K |
| National Science Foundation | Phase I | 2021 | $256K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.